DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 5, 2004, Pages 227-236

  Salama, Noha N ^a   Scott, Kenneth R ^b   Eddington, Natalie D ^a,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b HOWARD UNIVERSITY   (United States)

^c HSF II   (United States)

Author keywords

Anti HIV; Antiviral drugs; Bioavailability; DM27; Enaminones

Indexed keywords

3 [N (4 CHLOROPHENYL)AMINO] 5 METHYL 2 CYCLOHEXENONE; ACICLOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CARBON 14; DM 27; ENAMINONE; GLYCOPROTEIN P INHIBITOR; MANNITOL; PACLITAXEL; PROPRANOLOL; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; THIAZOLE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CELL STRAIN CACO 2; CYTOTOXICITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY;

ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CYCLOHEXANES; CYCLOHEXANONES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; P-GLYCOPROTEIN;

EID: 4043062217     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.404     Document Type: Article

References (33)

1. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 1999; 39: 211-238.
2. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
3. Kwei GY, Alvaro RF, Chen Q, et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 1999; 27: 581-587.
4. Sparreboom A, Asperen JV, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-2035.
5. Chiou WL, Chung SM, Wu TC. Commentary: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 2000; 17: 901-903.
6. Cox DS, Scott KR, Gao H, Raje S, Eddington ND. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants. J Pharm Sci 2001; 90: 1540-1552.
7. Eddington ND, Cox DS, Roberts RR, Stables JP, Powell CB, Scott KR. Enaminones - versatile therapeutic pharmacophores. Further advances. Curr Med Chem 2000; 7: 417-536.
8. Cox DS, Scott KR, Gao H, Raje S, Eddington ND. Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin. Eur J Pharm Biopharm 2001; 52: 145-150.
9. Scott KR, Edafiogho IO, Richardson EL, et al. Synthesis and anticonvulsant activity of enaminones. 2. Further structure-activity correlations. J Med Chem 1993; 36: 1947-1955.
10. Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carr Syst 1991; 8: 305-330.
11. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96: 736-749.
12. Salama NN, Scott KR, Eddington ND. In vitro and in vivo functional evaluation of the enaminones as a novel series of P-glycoprotein modulators for different therapeutic agents. In 18th Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October 26-30, 2003, Salt Lake City, Utah. 2003; (abstr).
13. Salama NN, Scott KR, Eddington ND. The influence of enaminones on the transport and oral bioavailability of P-gp substrate therapeutic agents. Int J Pharm 2004; 273: 135-147.
14. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-191.
15. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209.
16. Stouch TR, Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 2002; 54: 315-328.
17. Troutman MD, Thakker DR. Efflux ratios cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 2003; 20: 1200-1209.
18. Troutman MD, Thakker DR. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in intestinal epithelium. Pharm Res 2003; 20: 1210-1223.
19. Walle UK, Walle T. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 1998; 26: 343-346.
20. Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glcoprotein inhibitor KR30031. Pharm Res 2003; 20: 24-30.
21. Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 1999; 16: 1366-1372.
22. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-4602.
23. Seelig A. How does P-glycoprotein recognize its substrates? Int J Clin Pharmacol Ther 1998; 36: 50-54.
24. Salama NN, Eddington ND, Payne D, Wilson TL, Scott KR. Multidrug resistance and anticonvulsants: New studies with the enaminones. Curr Med Chem 2004; 11: 763-771.
25. Krenitsky TA, Hall WW, de Miranda P, Beauchamp LM, Schaeffer HJ, Whiteman PD. 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. Proc Natl Acad Sci USA 1984; 81: 3209-3213.
26. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-304.
27. Guengerich FP. In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 1996; 24: 521-533.
28. Sababi M, Borga O, Hultkvist-Bengtsson U. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur J Pharm Sci 2001; 14: 21-27.
29. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201-214.
30. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmacol Res 1999; 16: 408-414.
31. Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddc), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 2002; 80: 392-404.
32. Leung S, Bendayan R. Role of P-glycoprotein in the renal transport of dideoxyriucleoside analog drugs. Can J Physiol Pharmacol 1999; 77: 625-630.
33. Ford JM. Modulators of multidrug resistance. Preclinical studies. Hemato Oncol Clin North Am 1995; 9: 337-361.